MRI/Fusion with Ultrasound and the BioJet™ Technology 

Researchers agree that fusing MRI and ultrasound may be a better way to detect and evaluate prostate cancer, while avoiding unnecessary biopsies. This technology blends real-time imaging from ultrasound devices and MRI allowing physicians to more accurately direct the biopsy needle that draws cell samples from suspected tumors.

The technology is part of an overall approach to use MRI scans to determine which men need to undergo prostate biopsy and then use MRI/ultrasound fusion to perform the most efficient biopsy possible.  The images from the earlier MRI screening are overlaid with the real-time ultrasound images to provide visible targets for the physician to biopsy.  The BioJet™ technology is one of several MR/Fusion target biopsy platforms currently in the market, however it is the only true mobile platform available that offers simple and user friendly motion compensation combined with precise co-registration that allows the physician to use such innovative technology in their office setting. The BioJet™ platform supports both transrectal and transperineal biopsy procedures. 

The BioJet™ technology was founded in Germany by Dr. Peter Klews. The BioJet™ platform is registered among others in: Europe, Russia, Japan, Australia, and the United States. Our equipment is well known and in daily use all over the world.